Arbeitsgruppe Hepatobiliäre Tumoren - Studien
HCC - frühes Stadium

AIO-assoziierte Studie
www.clinicaltrials.gov zur Studie

AIO-HEP-0417/ass: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC) (IMMULAB)

--- in Rekrutierung ---
HCC - intermediäres Stadium

AIO-assoziierte Studie Für weitere Zentren offen 
 
zur Studie
  AIO-HEP-0220/ass:  Transarterial chemoembolization (TACE) with Irinotecan and Mitomycin C versus TACE with Doxorubicin in patients with Hepatocellular carcinoma not amenable to curative treatment - IRITACE- a randomized multicenter phase 2 trial. A trial of the German Alliance for Liver Cancer (GALC). - IRITACE 
  --- in Rekrutierung ---

AIO-Studie weitere Zentren auf Anfrage 
www.clinicaltrials.gov zur Studie
  AIO-HEP-0418: A randomized, 2-arm non-comparative phase II study on the effects of atezolizumab and Roche bevacizumab (atezo/bev) followed by on-demand selective TACE (sdTACE) upon detection of disease progression or of initial synchronous treatment with TACE and atezo/bev on 24-Months survival rate in the treatment of BCLC B hepatocellular carcinoma patients. (DEMAND)
  --- in Vorbereitung ---

AIO-assoziierte Studie Für weitere Zentren offen 
 
zur Studie
  AIO-HEP-0319/ass: A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with either Y-90 SIRT or TACE for intermediate stage HCC with pick-the-winner design - IMMUWIN
  --- in Rekrutierung ---
HCC - fortgeschrittenes Stadium, 1st-line

AIO-assoziierte Studie
www.clinicaltrials.gov zur Studie
  AIO-HEP-0218/ass: An open-label, single-arm phase II study of immunotherapy with nivolumab in combination with lenvatinib for advanced stage hepatocellular carcinoma (HCC) [IMMUNIB]
  --- in Rekrutierung ---
HCC - fortgeschrittenes Stadium, 2nd-line

AIO-assoziierte Studie
www.clinicaltrials.gov zur Studie

AIO-HEP-0320/ass: A phase II study evaluating reduced starting dose and dose escalation of Cabozantinib as second-line therapy for advanced HCC in patients with compensated liver cirrhosis (CaboRISE)

--- in Rekrutierung---

AIO-assoziierte Studie
www.clinicaltrials.gov zur Studie

AIO- HEP-0419/ass:   A Phase II, non-randomized, single arm, translational study of CAbozantinib for Patients with HepatocellUlaR CarcinOma (HCC) Refractory to LenvAtinib Treatment  (AURORA)

--- in Rekrutierung---

AIO-assoziierte Studie
www.clinicaltrials.gov zur Studie

AIO-HEP-0318/ass: A phase I/II multicenter, open-label Study of DKN-01 to investigate the anti-tumor activity and safety of DKN-01 in Patients with Hepatocellular Carcinoma and WNT signaling Alterations

--- in Rekrutierung---
CCA - adjuvant

AIO-Studie   www.clinicaltrials.gov zur Studie

AIO-HEP-0112: Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1). A randomized, multidisciplinary, multinational AIO/DGAV/DGVS phase III trial
  ---in Rekrutierung---
CCA - neoadjuvant

AIO-assoziierte Studie Für weitere Zentren offen www.clinicaltrials.gov zur Studie

AIO-HEP-0118/ass: Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) – A phase III study utilizing the German Registry of Incidental Gallbladder Carcinoma Platform (GR)
– The AIO/ CALGP/ ACO- GAIN-Trial -
  ---in Rekrutierung --- weitere Zentren sind sehr erwünscht! ---

AIO-Studie
www.clinicaltrials.gov zur Studie

AIO-HEP-0120:  Neoadjuvante Therapie mit Bintrafusp alfa bei Patienten mit operablem Krebs der Gallenwege (NEOBIL)
  --- in Vorbereitung ---
Biliäre Tumoren - 1st-line

AIO-assoziierte Studie Für weitere Zentren offen  www.clinicaltrials.gov  zur Studie
  AIO-HEP-0119/ass: A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of care [IMMUWHY]
  --- in Rekrutierung ---
Biliäre Tumoren - 2nd-line

AIO-Studie
www.clinicaltrials.gov zur Studie

AIO-HEP-0116: A randomized phase II trial of nal-IRI and 5-Fluorouracil compared to 5-Fluorouracil in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine or gemcitabine containing therapies (NALIRICC)
  ---in Rekrutierung---

AIO-Studie   www.drks.de zur Studie

AIO-YMO/HEP-0316: 5-Fluorouracil (5-FU), folinic acid and irinotecan (FOLFIRI) versus 5-FU and folinic acid as second-line chemotherapy in patients with biliary tract cancer (IRIBIL): a randomized open-label phase 2 study (IRIBIL)
  ---in Rekrutierung---
Register: Hepatozelluläres Karzinom / Gallengangskarzinom / Gallenblasenkarzinom / Pankreaskarzinom /  Magen- und Speiseröhrenkarzinom – palliativ, 1st-line

AIO-assoziierte Studie Für weitere Zentren offen  www.clinicaltrials.gov  zur Studie
  AIO-HEP/STO-0219/ass: PLATON Pilot-StudyPlatform for Analyzing Targetable Tumor Mutations – PLATON (Pilot-Study) and The PLATON Network (Main-Study)
  --- in Rekrutierung ---
LETZTE AKTUALISIERUNG DIESER SEITE AM: 16.11.2020